Introduction
frequent cystoscopic monitoring of patients a requirement of disease management [1, 2] . The diagnosis of bladder cancer relies heavily on direct cystoscopic examination of the bladder which enables Recurrence rates can be reduced markedly by instillation chemotherapy at initial diagnosis [3] , but until the surgeon to biopsy and resect tumours [1, 2] . Such resection is curative for #20% of patients, but this recently no mechanism has been available to discriminate between patients at risk of recurrence and those for success is limited to patients with noninvasive or only locally invasive primary TCC (pTa/pT1). About one in whom such chemotherapy would be unwarranted. As a result many urologists prefer to defer chemotherapy until five patients present with advanced disease (pT2-4) at diagnosis [1,2]. Overall, 70% of patients presenting with recurrence is detected (Scottish Urological Oncology Group, personal communications) to avoid over-treating TCC are destined to have recurrence, the risk of which is a function of time, although most patients will have patients who do not recur and exposing such patients to the genotoxic aCects of chemotherapy without cause. recurrence within 2-4 years of diagnosis. Uniquely amongst cancers, patients who experience one recurMolecular markers which predict recurrence have been detected by our previous research [4-6] and identify rence almost inevitably return with further episodes of recurrent disease such that the patient requires frequent patients most likely to benefit from regular cystoscopic surveillance and/or instillation chemotherapy at primary hospitalization to monitor disease recurrences [1,2]. Furthermore, a significant proportion of patients with diagnosis. Abnormalities of chromosomes 7, 9 and 17 have been shown to predict recurrence in up to 65% of recurrent disease will develop aggressive detrusor muscle invasive tumours (10-20% of patients [1,2]). The high patients at primary diagnosis [7] . The challenge is to expand these findings and increase the eBciency of such tests before their acceptance into clinical diagnostic Accepted for publication 1 June 1999 medicine. To achieve this goal it is first necessary to Luton, Beds, UK) for digoxigenin-labelled probes. This protocol yielded easily quantifiable results of equal colour determine the nature of the genetic alterations detected.
The development and progression of tumours, includintensity for all probes. The signals were visualized using an epifluorescence ing TCC, is driven by an accumulation of genetic abnormalities [8] [9] [10] [11] [12] [13] [14] [15] . Whilst chromosome-specific microscope (Leica, Milton Keynes, UK), with a 100-W mercury arc lamp, and photomicrography performed abnormalities are frequently described, polyploidy is also a frequent event in tumours and TCC is no exception using a Wild 48/52 photoautomat system (Leica, UK).
Regions for analysis by FISH were identified by examin- [12] [13] [14] . The evaluation of panels of two or three chromosomal markers may fail to detect tumour polying H&E-stained slides and areas to be scored marked on an enlarged photocopy (200%) of the section. Signals ploidy and lead to a misunderstanding of the tumour genetic profile. We have therefore expanded our previous for each chromosome in at least 200 discrete nuclei in control and carcinoma sections were counted using a studies of chromosomes 7, 9 and 17 to determine whether numerical aberrations occurred as a result of multichannel counter. The number of signals (0-8) were recorded. One to three tumour areas were analysed, and or independently from tumour polyploidy. We have further studied 25 of the 54 primary tumours from a proportion by three independent observers. As a measure of overall chromosomal copy number, patients with TCC that either recurred (32) or did not (22), described previously [4-7], a proportion of whom the mean chromosomal copy number (MCCN) was computed as the total number of hybridization signals divided also progressed to detrusor muscle invasion (11) . Fluorescence in situ hybridization (FISH) data for chroby the total number of nuclei. Monosomy was assessed by criteria previously defined [4] . Normal ranges for mosomes 7, 9 and 17 were available for all 54 tumours; FISH analysis for chromosomes 8, 10 and 11 was MCCN and monosomy were defined as the mean ±3 sd.
Polysomy was defined as tumours with Á10% of cells performed on the 25 primary tumours selected from these groups and quantitative analysis of chromosome with Á3 signals per nucleus [12] [13] [14] . The mean result from all tumour areas (2-3 per tumour) was calculated copy number obtained.
to give an overall value for each tumour event.
Materials and methods Results
The 25 primary tumours selected for this retrospective study represent the spectrum of genetic alterations seen FISH in the previous study (monosomy chromosome 9, aneusomy chromosomes 7 and 17. and apparent normoFor chromosomes 7, 9 and 17, our previous reports indicated that 24% of primary tumours (13 of 54) somy). The pathology for all tumours was reviewed following the UICC 1978 guidelines [16] .
showed loss of one copy of chromosome 9 [1]; 19% of primary tumours (10 of 54) showed increased copy Morphologically normal disomic urinary bladder epithelium served as a quality control for the FISH method.
numbers for either chromosome 7 or 17 or both [5] [6] [7] and one patient also had an increased copy number of Both normal tissues and tumours were accessed from participating pathology laboratories (Departments of chromosome 9. Only 3.7% of primary tumours showed simultaneous loss of chromosome 9 and gain of chromoPathology at Glasgow and Edinburgh Royal Infirmaries) and serial sections of the formalin-fixed, paraBn waxsomes 7 and 17 [5] [6] [7] . Both monosomy of chromosome 9 (P=0.0016) and polysomy of 7 and 17 (P=0.0095) embedded tissues were cut onto silane-coated slides for analysis. All tumours analysed had a representative were significantly associated with tumour recurrence, being almost exclusively detected in primary tumours section stained with haematoxylin and eosin (H&E), and were re-staged and re-graded by one specialist from patients who exhibited recurrence as described previously [4] [5] [6] [7] . pathologist (K.M.G.) following the UICC 1978 guidelines [16] .
For chromosomes 8, 10 and 11, in 25 selected primary tumours from our previous study, 32% (eight of 25) Dual-target FISH was performed with satellite repeat sequence DNA probes for chromosomes 7, 8, 9, 10, 11 showed no abnormalities in any of the chromosomes tested, either in this study or previously (chromosomes and 17, as described previously [4, 5] . Hybridization was visualized with fluorescein isothiocyanate (FITC) avidin, 7-11 and 17, data not shown). Nine of the remaining 17 primary tumours had one abnormality (Table 1) . Of biotinylated anti-avidin and then the signal-amplified with an additional FITC-avidin step (Vector Laboratories, these, five were monosomic for chromosome 9 whilst normal for all other chromosomes evaluated, two were Burlingame, CA) for biotinylated probes, and with sheep antidioxigenin (Boehringer Mannheim, Lewes, East polysomic for chromosome 17 and two were newly identified as polysomic for chromosome 8. Sussex, UK), FITC donkey antisheep (Stratech Scientific, Four tumours had abnormalities in two or three Of the G1 tumours, four showed no chromosomal abnormalities, two showed monosomy 9 and three chromosomes; of these, three were monosomic for chromosome 9 (Table 1) . Additional lesions were polysomy showed multiple alterations (maximum five chromosomes). Of G2 tumours, three showed no chromosomal 17, polysomy 8 or monosomy 10 (one case each). One tumour showed polysomy for chromosomes 7, 8 and 17
abnormalities, four showed alterations aCecting single chromosomes and two showed alterations involving with no alterations in chromosomes 9, 10 or 11 (Table 1) , although the copy number for chromosome multiple chromosomes (up to 3). Of G3 tumours, one showed no alterations, three showed aneusomy of one 10 was at the low end of the normal range.
Only four cases had abnormalities in more than three chromosome and three showed aneusomy of multiple chromosomes. chromosomes; of these, one was polysomic for all six chromosomes tested (Table 1) , suggesting a possible polyploidy. Of the remaining tumours, two were normal Discussion for chromosome 9 but polysomic for all other chromosomes tested, and one was polysomic for chromosomes
In our recent studies we identified aneusomy of chromosomes 9, 7 and 17 as potential risk factors for recurrence 7, 8, 11 and 17, monosomic for chromosome 9 and normal for chromosome 10. in TCC of the urinary bladder [4] [5] [6] [7] . Monosomy for chromosome 9 or polysomy for chromosomes 7 and 17 were associated significantly with subsequent disease Stage and grade recurrence in a retrospective cohort analysis [4] [5] [6] [7] . As it is possible that these changes reflect wider genetic Of the 25 tumours analysed for all chromosomes, 15 were pTa, nine pT1 and one pT2, and nine were grade damage such as tumour polyploidy we extended the studies to encompass chromosomes infrequently involved 1, nine grade 2 and seven grade 3. Of the 15 pTa tumours, six showed no chromosomal abnormalities, in genetic alterations in TCC (chromosomes 10 and 11) and included analysis of chromosome 8. Abnormalities five showed alterations of single chromosomes and four showed multiple aneusomic events. Of the 10 pT1/2 in chromosomes 8, 10 and 11 are more frequently associated with disease progression. tumours, two showed no abnormalities, three showed alterations of single chromosomes (including the pT2
The results presented here suggest that: (i) monosomy 9 occurs independently other chromosomal abnormalitumour) and five showed alterations of multiple chromosomes.
ties; (ii) polysomy of chromosomes 7 and 17 appears, in most cases, to occur in tandem, as in renal cell cancers [4] [5] [6] [7] . However, neither lesion is significantly associated with progression to higher tumour stage [4] [5] [6] [7] . It would [17] , but may also be associated with other chromosomal changes; (iii) these lesions are rarely associated with appear that these events are linked with superficial or locally invasive (pTa/pT1) tumour recurrence, therefore tumour polyploidy.
Monosomy 9 occurred independently of other lesions, we proposed that genes on these chromosomes are specifically involved in the process of tumour recurrence, although in some tumours abnormalities of other chromosomes were identified; half of the present tumours as distinct from tumour invasion [4] [5] [6] [7] .
In conclusion, following our recent studies identifying investigated showed monosomy 9 alone. In the other tumours, monosomy 9 was identified in the presence of genetic variables predictive of recurrence, the present results exclude tumour polyploidy as the underlying polysomy 8, 7 or 7 and 17, and monosomy 10. No clear pattern emerged to associate changes in chromosome 9 genetic event and show that aneusomy of chromosome 9 or chromosomes 7 and 17 are discrete genetic events. with other chromosome abnormalities. This finding suggests that loss of chromosome 9 does not require other
The linkage between these events and tumour recurrence suggests that genes involved in tumour recurrence in gross chromosomal changes, nor does it necessarily drive further gross chromosomal alterations.
the absence of clinical progression are located on these candidate chromosomes, as previously hypothesized. In >80% of cases both chromosomes 7 and 17 were polysomic, to a similar degree as that reported previously for renal cell cancers [17] . From the evidence presented
